- EMEA
- Our innovation
- Focus areas
- Immunology
- Psoriasis
- Freedom from disease

In a recent study, a large group of patients, doctors and nurses helped build a consensus about what freedom from disease looks like in psoriasis.[3] They identified five core domains that need to be addressed for freedom from disease to be achieved:
- Quality of life and well-being
- Treatment
- Healthcare team support
- Psychosocial elements
- Management of clinical symptoms
These results will help foster better communication between doctors, nurses and their patients and lead to better understanding and improvements in the care of psoriasis.
-
NeedsA better understanding of the overall needs of people with psoriasis can ensure that individual needs are better met.[2],[4]
-
VoiceListening to and amplifying the voices of people with psoriasis will further improve standards of care.[4],[5]
-
TreatmentChanging the treatment paradigm will enable all people with psoriasis to benefit from the full potential of new therapies.[2],[4]
-
Clinical toolsNew ways of assessing severity and measuring clinical response will facilitate new standards in freedom from disease.[5]
Learn more about the consensus statement published in JEADV
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
-
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
-
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
-
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
-
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
References
[1] Janssen. Immunology – Psoriasis. Available at: https://www.janssen.com/emea/our-focus/immunology/psoriasis. Accessed January 2023.
[2] Michalek IM and Loring B. World Health Organization: Global report on psoriasis. Available at: https://www.who.int/publications/i/item/9789241565189. Accessed January 2023.
[3] van Ee I, et al. Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. J Eur Acad Dermatol Venereol. 2022:36(3):403–412.
[4] Grine L, et al. A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management. J Eur Acad Dermatol Venereol. 2020:34(4):676–684.
[5] Strober BE, et al. Clinical Goals and Barriers to Effective Psoriasis Care. Dermatol Ther (Heidelb). 2019:9(1):5–18.
CP-459038
September 2024